The American pharmaceutical company Merck plans to acquire oncology specialists | News

Apparently, the first big thing this year is coming to the pharmaceutical industry. Acquisition talks between the US drugmaker and biotechnology firm Seagen, which specializes in anti-cancer drugs, are expected to be sealed by July 28, at the latest, when Merck announces its quarterly figures.

According to media reports, both companies are in advanced acquisition talks. The price of $ 200 per Seagen share is being discussed. The deal could be worth around $ 40 billion. Seagen has several cancer drugs in clinical trials and four drugs approved. Together, they brought in sales in excess of one billion dollars last year.

The acquisition could strengthen Merck’s portfolio before its blockbuster Keytruda cancer immunotherapy loses its marketing exclusivity in 2028. Keytruda’s revenue for the past year was $ 17.2 billion, a good 35 percent of total revenue.

Register now and buy Merck Stock

More: https://www.etoro.com/ CFDs are complex instruments and come with a high risk of losing money rapidly through leverage. 67% of retail investor accounts lose money when trading CFDs from this provider. You should consider whether you understand how CFDs work and whether you can afford the high risk of losing your money.

If the deal is successful, it will be the first major deal in the pharmaceutical industry this year. In 2021, the British pharmaceutical company AstraZeneca acquired the American biotechnology company Alexion for 39 billion dollars, for AstraZeneca it was by far the largest acquisition. Recently, several large deals have been canceled amid falling stock prices and rising borrowing costs, including the sale of UK pharmacy chain Boots by Walgreens.

Merck’s share at a record level

Merck shares have been in a strong uptrend since late February and the 200-day moving average (red) is now turning upwards as well. The MACD (Momentum) is also pointing to an increase and is supporting the stocks in another attempt to hit a record high of just above 95 EUR.

Merck’s success can be attributed purchase of shares participate. Brave investors can get leverage with Buy CFDs get involved.

It’s that simple to buy stocks on eToro.

The eToro platform offers traders from all over the world the unique opportunity to add shares to their portfolio. As of early 2018, every BUY non-leveraged order causes eToro to buy the underlying asset; it will then be held on behalf of the client. This also applies to cases where you invest in CopyPortfolio or copy an investor: if the copied investor buys shares, you automatically own a portion of his share portfolio.

Trade stocks with eToro, here are the advantages:

  • trust Your shares will be held in your name in an EU regulated company.
  • insurance Your deposit and related assets are insured under CySEC’s Terms of Use.
  • dividends If the company pays dividends, investors will be allocated an appropriate dividend.
  • No care fees Buying stocks on eToro means you no Pay storage and ordering fees as well as commissions. There is a bid-ask spread when buying and selling stocks.
  • Easy-to-use Your warehouse is always available online and via the app.
  • diversification Create a portfolio of stocks, cryptocurrencies, commodities, and more.

Register now and buy stocks

About eToro:

For over a decade, eToro has been at the forefront of the global fintech revolution. It is the world’s leading social trading network, with millions of registered users and a host of innovative trading and investing tools. Since the beginning of 2018, eToro allows you to buy and sell stocks.

More: https://www.etoro.com/ CFDs are complex instruments and come with a high risk of losing money rapidly through leverage. 67% of retail investor accounts lose money when trading CFDs from this provider. You should consider whether you understand how CFDs work and whether you can afford the high risk of losing your money.

Leave a Comment